Novavax Inc (NVAX) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of disease...
Novavax Inc's revenue increased 64.7% year over year, from $682.2M to $1.12B.
Net income increased 334.8% over the same period, from $-187.5M to $440.3M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 7218% in total.
Operating cash flow declined 180.2% to $-244.6M.
Novavax Inc maintains a strong net profit margin of 39.2%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Equity |
|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $84.5M-79.7% | $-121.3M | $23.9M | $-134.0M | $-144.8M | $1.71B | $-526.4M |
| Q4 FY2024 | $88.3M+4.5% | $-81.0M | $51.6M | $-131.1M | $-173.2M | $1.56B | $-623.8M |
| Q1 FY2025 | $666.7M+654.9% | $518.6M | $652.5M | $515.5M | $-185.5M | $1.29B | $-75.6M |
| Q2 FY2025 | $239.2M-64.1% | $106.6M | $223.9M | $101.1M | $-127.5M | $1.34B | $37.6M |
| Q3 FY2025 | $70.4M-70.6% | $-202.4M | $48.9M | $-178.0M | $107.8M | $1.18B | $-156.7M |
| Q4 FY2025 | $147.1M+108.9% | $17.5M | $125.0M | $14.2M | $-39.4M | $1.18B | $-127.8M |
| Q1 FY2026 | $139.5M-5.2% | $-9.5M | $108.8M | $-15.4M | $-32.4M | N/A | N/A |
| Q2 FY2026 | $56.7M-59.4% | $-53.4M | $42.5M | $-54.9M | $-72.8M | N/A | N/A |
Balance Sheet Summary (FY2025)
Novavax Inc (NVAX) Financial Statements & Revenue History
Novavax Inc (NVAX) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry trading at $11.15 with a market capitalization of $2. This page provides 42 historical financial statements for Novavax Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Novavax Inc reported revenue of $1.1 billion, representing 64.7% year-over-year growth. The net profit margin of 39.2% reflects strong profitability..
NVAX Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Novavax Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether NVAX is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track NVAX's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Novavax Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of NVAX's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use NVAX Financial Data
Investors use Novavax Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare NVAX's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how NVAX's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View NVAX's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Novavax Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.NVAX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.